CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 143 enrolled
Drug / intervention
Lapatinib Ditosylate +3 moredrug
Likely dose
Lapatinib (dose not specified in interventions)AI-extracted
Key inclusion· 6
  • Histologically or cytologically confirmed invasive breast cancer
  • HER2-overexpressing breast cancer by IHC 3+ or FISH/SISH ≥2.0
  • At least 1 measurable unirradiated parenchymal brain metastasis; SRS patients limited to ≤10 metastases, WBRT unlimited; solitary lesion ≥10 mm, ≥2 lesions with ≥2 at ≥5 mm
  • Able to swallow and retain oral medication (suspension formulation acceptable)
Key exclusion· 9
  • Prior whole-brain radiotherapy
  • Prior radiation therapy at any site concurrent with lapatinib (same-day exposure)
  • Leptomeningeal disease
  • Uncontrolled intercurrent illness including active infection, symptomatic heart failure, unstable angina, arrhythmia, or psychiatric illness limiting compliance

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01622868
NCT01622868Phase 2Completed

Phase II Randomized Study of Whole Brain Radiotherapy/Stereotactic Radiosurgery in Combination With Concurrent Lapatinib in Patients With Brain Metastasis From HER2-Positive Breast Cancer - A Collaborative Study of NRG Oncology and KROG

National Cancer Institute (NCI)·interventional·Posted Jun 19, 2012·Updated Oct 17, 2023

In Brief

A Phase 2 clinical trial evaluating Laboratory Biomarker Analysis, Lapatinib Ditosylate, and 2 other interventions for HER2-Positive Breast Carcinoma and 4 related conditions. Completed, enrolled 143 participants across 302 sites in 3 countries.

Detailed Summary

This randomized phase II trial studies how well whole-brain radiation therapy or stereotactic radiosurgery with or without lapatinib ditosylate works in treating patients with breast cancer that has too many of a protein called human epidermal growth factor receptor 2 (HER2) on its cells and has spread to the brain. Radiation therapy uses high energy x rays to kill tumor cells and shrink tumors. Stereotactic radiosurgery is a specialized radiation therapy that delivers a single, high dose of radiation directly to the tumor and may kill more tumor cells and cause less damage to normal tissue. Lapatinib ditosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether whole-brain radiation therapy or stereotactic radiosurgery together with lapatinib ditosylate is an effective treatment for brain metastasis from breast cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesCanada, South Korea, United States
CollaboratorsNRG Oncology

Timeline

Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedJun 19, 2012
Enrollment StartDec 6, 2012
Primary CompletionDec 30, 2019
Study CompletionMay 20, 2022
TodayJul 2, 2026
Enrollment to primary: 7.1 yearsPosted 14.0 years ago

Interventions

Laboratory Biomarker Analysisother

Correlative studies

Lapatinib Ditosylatedrug

Given PO

Stereotactic Radiosurgeryradiation

Undergo SRS

Whole-Brain Radiotherapyradiation

Undergo WBRT